CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Real world experience in 150 genotype 1 HCV patients with triple therapy: severe adverse events and high rates of virological failure in cirrhotic patients with portal hypertension (platelets < 100.000/nl and albumine < 40 g/l)
DOI 10.1055/s-0033-1352750
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ Petersen, K Voelker, K Olah, K Matschenz, H Wolski, C Czaja-Harder, F Kuhlendahl, A Plettenberg, T Lorenzen, S Unger, A Stoehr, P Buggisch
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background and aim: Newly approved HCV GT1 triple regimens are complex and associated with additional toxicities. Besides RCT results, only limited data are available for BOC und TVR under real life conditions, especially for difficult to treat patients with non-response and advanced liver disease. Methods: Data from 150 patients who initiated triple therapy apart from clinical studies or Early-Access-Programs with…
Zitieren
Zitierempfehlung
J Petersen, K Voelker, K Olah, K Matschenz, H Wolski, C Czaja-Harder, F Kuhlendahl, A Plettenberg, T Lorenzen, S Unger, A Stoehr, P Buggisch (2013) Real world experience in 150 genotype 1 HCV patients with triple therapy: severe adverse events and high rates of virological failure in cirrhotic patients with portal hypertension (platelets < 100.000/nl and albumine < 40 g/l). Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0033-1352750
Mit CareLit weiterarbeiten